Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RVMD | INST-CLUSTER | bullish | 4/10 | A massive institutional cluster formed in Revolution Medicines (RVMD) during Q2 2026, with 92 buyers accumulating $3.03B | Oct 12, 2026 |
| QNRX | ANALYST-UPGRADE | bullish | 4/10 | BTIG initiated coverage on Quoin Pharmaceuticals Ltd. (QNRX) with a Buy rating and a $14 price target, representing 213% | Oct 12, 2026 |
| ABT | ANALYST-UPGRADE | bullish | 4/10 | Barclays initiated coverage on ABBOTT LABORATORIES (ABT) at Overweight with a $120 price target, implying 19.9% upside f | Oct 12, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem filed a routine Form 6-K reporting treasury share holdings as of September 26, 2026. The filing confirms 27 Clas | Oct 9, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem S.A. filed a Form 6-K for October 2026, reporting insider trading activity for September 2026 under Brazilian CV | Oct 9, 2026 |
| GDTC | 6-K | bearish | 5/10 | CytoMed Therapeutics received a Nasdaq deficiency notice on October 6, 2026, for failing to maintain the $1.00 minimum b | Oct 9, 2026 |
| AVCRF | 6-K | bullish | 6/10 | Avricore Health announced that NHS England has confirmed the national expansion of the Barts Health pharmacy cholesterol | Oct 9, 2026 |
| OCGN | 144 | neutral | 2/10 | Ocugen CEO Shankar Musunuri filed a Form 144 notice of intent to sell 525,991 shares (~$498K at the filing date). The sh | Oct 9, 2026 |
| NUOX | S-1/A | neutral | 5/10 | NuvOx Therapeutics filed Amendment No. 2 to its S-1 registration statement for an IPO of 2,860,000 shares at an estimate | Oct 9, 2026 |
| RTSN | 424B4 | neutral | 5/10 | Retension Pharmaceuticals priced its IPO of 3,750,000 shares at $12.00 per share, raising gross proceeds of $45.0 millio | Oct 9, 2026 |
| GTBP | S-1 | bearish | 7/10 | GT Biopharma filed an S-1 registration statement to register up to 13,502,835 shares of common stock for resale by selli | Oct 9, 2026 |
| VNDA | SC 13G/A | neutral | 4/10 | Millennium Management LLC filed an amended Schedule 13G disclosing a 7.0% passive stake in Vanda Pharmaceuticals as of S | Oct 9, 2026 |
| GLPG | 6-K | neutral | 2/10 | Bank of America Corporation crossed below the 10% voting rights threshold in Lakefront Biotherapeutics, dropping to 8.54 | Oct 9, 2026 |
| SBFM | 8-K | bearish | 6/10 | Sunshine Biopharma closed a best-efforts public offering raising approximately $6.0 million in gross proceeds via 10,909 | Oct 9, 2026 |
| SBFM | 424B4 | bearish | 7/10 | Sunshine Biopharma priced a best-efforts offering of up to 10,509,082 Common Units at $0.55/unit, each consisting of one | Oct 9, 2026 |
| ACIU | 3/A | neutral | 2/10 | Thomas Graney filed an amended Form 3 (3/A) to add a Power of Attorney as Exhibit 24. The filing reports his beneficial | Oct 9, 2026 |
| QUCY | 8-K | neutral | 4/10 | Quantum Cyber N.V. entered into an at-the-market (ATM) sales agreement with Titan Partners Securities LLC to sell up to | Oct 9, 2026 |
| VTGN | 8-K | neutral | 3/10 | Vistagen Therapeutics adopted an amended and restated Executive Severance Plan on October 7, 2026, expanding severance b | Oct 9, 2026 |
| ARTL | 8-K | bearish | 5/10 | Artelo Biosciences disclosed that it was among ~180 Nasdaq-listed companies initially identified as having a market valu | Oct 9, 2026 |
| MBRX | 8-K | neutral | 4/10 | Moleculin Biotech held its 2026 Annual Meeting on October 9, 2026. Stockholders approved an amendment to the 2024 Stock | Oct 9, 2026 |
| QUCY | 424B5 | bearish | 7/10 | Quantum Cyber N.V. filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $100,000,000 | Oct 9, 2026 |
| SYRE | SC 13D/A | neutral | 3/10 | Fairmount Funds Management LLC filed Amendment No. 8 to its Schedule 13D on Spyre Therapeutics, reporting no change in b | Oct 9, 2026 |
| SXTC | 6-K | bearish | 7/10 | China SXT Pharmaceuticals (SXTC) filed a 6-K disclosing a securities purchase agreement for a registered direct offering | Oct 9, 2026 |
| PCVX | 8-K | bearish | 6/10 | Vaxcyte entered into a First Supplemental Indenture to issue $575M aggregate principal amount of 1.50% Convertible Senio | Oct 9, 2026 |
| GLASF | 6-K | neutral | 3/10 | Glass House Brands Inc. disclosed the planned retirement of CFO Mark Vendetti, effective March 31, 2027, with a successo | Oct 9, 2026 |
| VREOF | S-4 | neutral | 5/10 | Vireo Growth Inc. filed an S-4 registration statement for its acquisition of Planet 13 Holdings Inc. via a merger. Plane | Oct 9, 2026 |
| BIAF | 8-K | bearish | 6/10 | bioAffinity Technologies entered into a placement agency agreement and securities purchase agreement on October 8, 2026, | Oct 9, 2026 |
| HEPA | 8-K | mixed | 6/10 | Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences (GLS), a clinical-stage biotech developing op | Oct 9, 2026 |
| QTTB | SC 13G | neutral | 4/10 | Frazier Life Sciences Public Fund, L.P. filed a new Schedule 13G disclosing a 5.9% passive stake in Q32 Bio Inc., holdin | Oct 9, 2026 |
| TCRT | 8-K | bearish | 7/10 | Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, for failing to maintain the minimum $2. | Oct 9, 2026 |